Lasa Supergenerics Limited — Earnings Release 2020

Jun 8, 2020

==> picture [469 x 48] intentionally omitted <==

Ref. No.: LASA/SE/20-21/009

Monday June 08, 2020

To, To, Corporate Services Department Corporate Services Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. BSE CODE –540702 NSE CODE: LASA

Dear Sir/Madam,

Sub: Media Release

Attached is the copy of Media Release titled “Lasa Supergenerics Q4 PAT at 2.58Cr, up 243.33% YoY” issued by the company.

Kindly take the same on your records.

Thanking you Yours Sincerely FOR LASA SUPERGENERICS LIMITED

==> picture [472 x 65] intentionally omitted <==

NIDHI KULSHRESHTHA COMPANY SECRETARY AND COMPLIANCE OFFICER

==> picture [470 x 28] intentionally omitted <==

==> picture [139 x 81] intentionally omitted <==

Media Release

LASA SUPERGENERICS Q4 PAT AT 2.58CRS, UP 243.33% YOY

Mumbai,8[th] June 2020: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the fourth quarter and Financial Year ended March 31[st] , 2020.

Q4FY20 performance overview compared with Q3FY20

• Revenues from operations stood at Rs. 48.58crore

• EBITDA of Rs. 9.01 crore as compared to Rs. 8.48 crore in Q3FY20 o EBITDA margins at 18.55%

• PAT stood at Rs. 2.58 crore

• EPS for Q4FY20 stood at Rs. 0.89

FY20 performance overview compared with FY19

• Revenues from operations stoodat Rs. 167.27 crore

• EBITDA of Rs. 30.18 crore; y-o-y growth of 169.6%

• EBITDA margins at 18.04%

• PAT stood at Rs. 3.63 crore as compared to a loss of Rs. 12.04 crore in FY19

• EPS for FY20 stood at Rs. 1.26, as compared to Rs. -5.26 for FY19

For fourth quarter ended March 31[st] 2020

Revenues from operations for the fourth quarter ended March 31[st] , 2020(Q4FY20) at Rs. 48.58crore.

The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 9.01 crore in Q4FY20, as against Rs8.48crore in Q3FY20; up 7.8%. The Company’s EBITDA margin stood at18.55%

The Company reported PAT of Rs. 2.58crore for Q4FY20.The Company’s PAT margin stood at 5.31%

Earnings per share (EPS) for the quarter ended Q4FY20 stood at Rs0.89

For financial year ended 31[st] March 2020

Total Income for the FY20 ended 31st March 2020 at Rs. 167.27crore.

The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 29.95 crore in FY20, as against Rs 11.11crore in FY19; up 169.6%. The Company’s EBITDA margin improved from 6.55% in FY19 to 17.91% in FY20.

==> picture [139 x 81] intentionally omitted <==

The Company reported a healthy increasein its PAT to Rs. 3.63 crore for FY20, as compared to a loss of Rs. 12.04crore in the corresponding period last fiscal. The Company’s FY20 PAT margin stood at a robust 2.17%, as against -7.10% in FY19.

The finance cost reduced from 8.38 Crore in FY19 to Rs 8.10 crore in FY20

Post announcement of Q4 & FY20 results the stock price touched a high of Rs. 43.25 per share up 10%, in result day trade with a volume spurt of 8.43 times

Commenting on the performance, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited said,

”We are an ambitious and fast growing API company now, moving in the right direction such as foraying into other avenues i.e. steroids, anti-parasites, anti-microbial and ectoparaciticides. Our focus continues to be in anthelmintic where we hold a majority share.

Additionally, “The Company under the right leadership and skilled teams have turned net positive to now post a PAT.

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more information contact:

Mr. Hitesh Wadhwani Mr. Gaurav Girdhar Lasa Supergenerics Ltd. Concept Investor Relations Tel: 7798888147 Tel: +022 40558934 E-mail: hitesh@lasalabs.com M: +91 7798232425 Email:gaurav.g@conceptpr.com	Mr Shahab Shaikh / Amruta Desai Concept PR +91 9320897525/ +91 9867891235 shahab@conceptpr.com/amruta@conceptpr.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forwardlooking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forwardlooking statements to reflect subsequent events or circumstances.